A recent prospective imaging study determined that the overall prevalence of older adults with cerebral cavernous malformation (CCM) is 0.46%. The findings and data from this study are important for determining the potential number of patients available for cohort studies and anticipated clinical trials in patients with CCM. Researchers included 4,721 participants aged 50 to 89 years who were enrolled between January 1, 2004, and December 15, 2015, in the Mayo Clinic Study of Aging, a longitudinal, population-based study. Participants were invited to undergo brain magnetic resonance imaging (MRI). Of total participants, 2,715 had an evaluable MRI. They found:
- Of total participants who underwent MRI scans, 12 (0.44%) had CCM.
- With the use of inverse probability weights to adjust for participation bias, the overall prevalence was 0.46%.
- The age-adjusted prevalence was found to be 0.61% for the 50- to 59-year age group, 0.17% for the 60- to 69-year age group, 0.45% for the 70- to 79-year age group, and 0.58% for the 80- to 89-year age group.
- The sex-adjusted prevalence was 0.41% for women and 0.51% for men.
Flemming KD, Graff-Radford J, Aakre J, et al. Population-based prevalence of cerebral cavernous malformations in older adults. Mayo Clinic Study of Aging. [Published online ahead of print May 8, 2017]. JAMA Neurol. doi:10.1001/jamaneurol.2017.0439.
This Week's Must Reads
Guidelines for Cognitive Screening, Management of MS, Mult Scler; ePub 2018 Oct 10; Kalb, Beier, et al
Age a Critical Determent in MS Relapse Recovery, Mult Scler; ePub 2018 Oct 10; Conway, et al
Is Contrast MR Imaging Necessary for All Patients?, Am J Neuroradiol; ePub 2018 Oct 4; Mattay, et al
Link Between Physiological and Perceived Fall Risk, Arch Phys Med Rehab; 2018 Oct; Gunn, et al
Muscle Strength Key in Determining Gait Speed in MS, Mult Scler Relat Disord; ePub 2018 Oct 9; Yang, et al
Must Reads in Rare Diseases
Treatment Outcomes Post-Surgery for Moyamoya Disease, J Neurol; ePub 2018 Sep 8; Kahn, Kaur, Stein, et al
FDA Approves Drug for Rare Peripheral Nerve Disease, FDA Web site; 2018 Aug 10
FDA Approves Hizentra for CIDP Treatment, CSL Behring news release; 2018 Mar 16
Cerebral Cavernous Malformation in the Elderly , JAMA Neurol; ePub 2017 May 8; Flemming, et al
Austedo Approved to Treat Chorea in Huntington's Disease, Teva news release; 2017 Apr 3